Biosensor

The technology is an ultra-sensitive optical biosensor based on the FRET principle, designed for identifying the initial, pre-aggregated pathological form of the Tau protein (CST). The innovation lies in the ability to detect specific conformational changes (CST), providing a molecular advantage over concentration-only tests.

In vitro validation (TRL 3) has been successfully completed, demonstrating the sensor's effectiveness on:

A biosensor based on magnetic microspheres functionalized with a DNA-aptamer was developed for the specific biomonitoring of biological contaminants (mycotoxins) in urine.

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.